Related Experiment Video
Updated: Aug 4, 2026

Evaluating In Vitro DNA Damage Using Comet Assay
Published on: October 11, 2017
[Comparative study of three antineoplastic alkylating agents on DNA]
Cyclophosphane demonstrated superior anticancer effects with fewer side effects on liver DNA compared to phosphamide and sarcolysine. This alkylating agent is preferred for cancer treatment due to its targeted efficacy and reduced toxicity.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Alkylating anticancer agents are crucial in cancer therapy.
- Understanding their effects on DNA is vital for optimizing treatment.
- Selective toxicity between tumor and healthy tissue is a key goal.
Purpose of the Study:
- To investigate the impact of phosphamide, sarcolysine, and cyclophosphane on DNA methylation and thermal stability.
- To compare the anticancer efficacy and DNA-related side effects of these three agents.
- To determine the most preferable alkylating agent based on efficacy and safety.
Main Methods:
- Analysis of 5-methylcytosine content in liver and sarcoma 45 DNA.
- DNA melting parameter assessment for liver and tumor tissues.
- Comparative evaluation of three alkylating anticancer preparations.
Main Results:
- Cyclophosphane exhibited a stronger anticancer influence on sarcoma 45.
- Cyclophosphane demonstrated comparatively weaker side effects on liver DNA.
- Differences in 5-methylcytosine content and DNA melting parameters were observed across treatments.
Conclusions:
- Cyclophosphane is a preferable alkylating agent due to its balanced efficacy and safety profile.
- The study highlights the importance of evaluating drug-induced DNA modifications.
- Further research into cyclophosphane's mechanism and therapeutic potential is warranted.
More Related Videos
09:33Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
Published on: March 20, 2018
04:36Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
Related Concept Videos
DNA Damage can Stall the Cell Cycle
Mutagenicity and Carcinogenicity